Talecris Biotherapeutics, Inc., a biopharmaceutical company, engages in the production and marketing of plasma-derived protein therapies worldwide. It develops, produces, markets, and distributes therapies for the people suffering from chronic and acute, immune deficiency disorders, alpha-1 antitrypsin deficiency, infectious diseases, hemophilia, and severe burns. The companyâ€™s products include Gamunex, an intravenous immune globulin (IGIV) for the treatment of primary immune deficiency and autoimmune diseases; and Prolastin, an alpha-1 proteinase inhibitor (A1PI) for the treatment of alpha-1 antitrypsin deficiency-related emphysema. It also offers Hyperimmunes, which are antibody preparations for hepatitis, rabies, tetanus, and treatment of Rh negative women pregnant with Rh positive children; and albumin under various brand names, including Plasbumin albumin and Plasmanate plasma protein factor. In addition, the company provides plasma-derived hemostasis products to treat patients who lack the necessary factors for blood clotting and suffer from conditions in which clotting occurs; and PPF-powder for the fermentation of Kogenate. Talecris Biotherapeutics, Inc. was incorporated in 2004 and is based in Research Triangle Park, North Carolina.